Management & Regulatory

With deep expertise in biopharma innovation and oncology research and development, Ivan Kairatov offers a unique perspective on the latest breakthroughs in cancer treatment. Today, we delve into the recent positive opinion from European regulators for AstraZeneca’s Imfinzi in combination with

For individuals grappling with the relentless and often disfiguring effects of cutaneous lupus erythematosus, the path to effective treatment has been long and fraught with limited options, but a significant development from Biogen offers a new beacon of hope. The U.S. Food and Drug Administration

In a world grappling with the compounding pressures of global conflict and environmental disasters, the very foundation of public health is being tested, revealing deep-seated inequities that threaten our collective future. The challenge is no longer merely about treating disease but about

The intricate web of modern healthcare technology, designed to streamline patient care, has once again demonstrated its potential vulnerability after a significant data breach at a third-party vendor exposed the sensitive records of patients from Jupiter Medical Center. The incident, which did not

For many individuals on a weight management journey, hitting a plateau can feel like an insurmountable barrier, but a new, higher dosage of a well-known medication aims to break through that very wall. This review assesses the clinical significance and therapeutic value of the newly approved 7.2mg

The relentless cycle of flare-ups for those with severe Chronic Obstructive Pulmonary Disease has long demanded a more precise therapeutic weapon, a need the UK's health authorities have now addressed with a new approval. This review evaluates Nucala (mepolizumab), recently authorized by the MHRA